File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Consensus recommendations for the screening, diagnosis, and management of Helicobacter pylori infection in Hong Kong

TitleConsensus recommendations for the screening, diagnosis, and management of Helicobacter pylori infection in Hong Kong
Authors
Issue Date30-Jun-2023
PublisherHong Kong Academy of Medicine Press
Citation
Hong Kong Medical Journal, 2023, v. 29 How to Cite?
Abstract

Helicobacter pylori infection causes chronic gastric inflammation that contributes to various gastroduodenal diseases, including peptic ulcer and gastric cancer. Despite broad regional variations, the prevalence of resistance to antibiotics used to manage H pylori infection is increasing worldwide; this trend could hinder the success of eradication therapy. To increase awareness of H pylori and improve the diagnosis and treatment of its infection in Hong Kong, our consensus panel proposed a set of guidance statements for disease management. We conducted a comprehensive review of literature published during 2011 and 2021, with a focus on articles from Hong Kong or other regions of China. We evaluated the evidence using the Oxford Centre for Evidence-Based Medicine’s 2011 Levels of Evidence and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system and sought consensus through online voting and a subsequent face-to-face meeting, which enabled us to develop and refine the guidance statements. This report consists of 24 statements regarding the epidemiology and burden, screening and diagnosis, and treatment of H pylori. Key guidance statements include a recommendation to use the test-and-treat approach for high-risk individuals, as well as the confirmation that triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin remains a valid first-line option for adults and children in Hong Kong.


Persistent Identifierhttp://hdl.handle.net/10722/329187
ISSN
2023 Impact Factor: 3.1
2023 SCImago Journal Rankings: 0.261

 

DC FieldValueLanguage
dc.contributor.authorLeung, WK-
dc.contributor.authorCheung, KS-
dc.contributor.authorSham, PCO-
dc.contributor.authorTang, RSY-
dc.contributor.authorLoo, CK-
dc.contributor.authorHsu, ASJ-
dc.contributor.authorCheung, TK-
dc.contributor.authorLam, LY-
dc.contributor.authorChiu, BCF-
dc.contributor.authorWu, JCY -
dc.date.accessioned2023-08-05T07:55:57Z-
dc.date.available2023-08-05T07:55:57Z-
dc.date.issued2023-06-30-
dc.identifier.citationHong Kong Medical Journal, 2023, v. 29-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/329187-
dc.description.abstract<p><em>Helicobacter pylori</em> infection causes chronic gastric inflammation that contributes to various gastroduodenal diseases, including peptic ulcer and gastric cancer. Despite broad regional variations, the prevalence of resistance to antibiotics used to manage <em>H pylori</em> infection is increasing worldwide; this trend could hinder the success of eradication therapy. To increase awareness of <em>H pylori</em> and improve the diagnosis and treatment of its infection in Hong Kong, our consensus panel proposed a set of guidance statements for disease management. We conducted a comprehensive review of literature published during 2011 and 2021, with a focus on articles from Hong Kong or other regions of China. We evaluated the evidence using the Oxford Centre for Evidence-Based Medicine’s 2011 Levels of Evidence and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system and sought consensus through online voting and a subsequent face-to-face meeting, which enabled us to develop and refine the guidance statements. This report consists of 24 statements regarding the epidemiology and burden, screening and diagnosis, and treatment of <em>H pylori</em>. Key guidance statements include a recommendation to use the test-and-treat approach for high-risk individuals, as well as the confirmation that triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin remains a valid first-line option for adults and children in Hong Kong.</p>-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press-
dc.relation.ispartofHong Kong Medical Journal-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleConsensus recommendations for the screening, diagnosis, and management of Helicobacter pylori infection in Hong Kong-
dc.typeArticle-
dc.identifier.doi10.12809/hkmj2210321-
dc.identifier.volume29-
dc.identifier.eissn2226-8707-
dc.identifier.issnl1024-2708-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats